The Distributors Intuitive Is Buying BackNarrow moat

Intuitive Surgical (ISRG) — moat facet

The sale is not the relationship; the field presence afterwards is, which is why Italy, Spain and Portugal have just been taken in-house.

Intuitive sells directly in the United States, most of Europe, China through its joint venture, Japan, South Korea, India, Taiwan and Canada; everywhere else it sells through distributors, and it uses distributors alongside its own force in China, Japan and for some United States government customers1.

Taking the field presence in-houseMarkets moved to direct in 2026Italy, Spain, PortugalWhat it costsInside the $2,385.0M of SG&ARevenue outside the United States32% of the totalProcedures outside the United States36% of the totalInternational revenue per procedure is lower than domestic, which is what the gap between 32% and 36% says.
The sale is not the relationship. Each buy-back converts a margin paid away into people Intuitive employs in the operating room.

The direction of travel is toward direct. During 2026 Intuitive completed the acquisition of the da Vinci and Ion distribution businesses in Italy, Spain and Portugal and began the transition from a distributor to a direct sales model in those markets2 — three of the four European countries the 10-K had previously listed as distributor territories.

The logic is the same as everywhere else in this company. The value in the relationship is not the sale; it is the clinical presence afterwards — the field force that sits in operating rooms, develops programmes, trains teams and drives utilisation. A distributor sells the system and then owns the customer relationship that Intuitive needs to compound the recurring revenue.

It also captures the distributor's margin, which is why the transition shows up as a revenue and cost event rather than only a strategic one. Intuitive lists the integration of these acquisitions among its forward-looking risks3.

The cost is that direct operations carry direct expense. Selling, general and administrative costs were $2,385.0 million in 20254, and every market taken in-house adds people, offices and local regulatory obligations before it adds a single procedure.

Compare outside-the-United-States revenue with OUS procedures. OUS was 32% of revenue and 36% of da Vinci procedures in 20255, so international cases still generate less revenue each than domestic ones. Converting distributors to direct is one of the few levers that closes that gap without changing a single price.

Moat trajectory: Widening

Italy, Spain and Portugal moved from distributors to direct in 2026. Each buy-back converts a margin paid away into a relationship owned, and Intuitive has said more are possible.

The number that tests this moat
Moat Explorer calc
Instruments and accessories revenue outside the U.S.
$1,815.5M in 2025, up 25%

Taking markets direct is meant to raise usage of systems already installed. This growth staying ahead of the U.S. rate would show the buy-backs working.

How it's calculated: OUS instruments and accessories revenue of $1,815.5M in 2025 against $1,452.6M in 2024.
Source: Intuitive Surgical Form 10-K, FY2025 ↗
References
  1. ReportedIntuitive sells directly in the United States, most of Europe, China through its joint venture, Japan, South Korea, India, Taiwan and Canada; everywhere else it sells through distributors, and it uses distributors alongside its own force...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedDuring 2026 Intuitive completed the acquisition of the da Vinci and Ion distribution businesses in Italy, Spain and Portugal and began the transition from a distributor to a direct sales model in those markets — three of the four European...
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  3. ReportedIntuitive lists the integration of these acquisitions among its forward-looking risks.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1A Risk Factors (the 559-system Chinese quota and Intuitive's placements under it, provincial limits on what hospitals may charge for robotic surgery, hospital financial pressure, and the warning that it may not recuperate the cost of a leased system) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedSelling, general and administrative costs were $2,385.0 million in 2025, and every market taken in-house adds people, offices and local regulatory obligations before it adds a single procedure.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedOUS was 32% of revenue and 36% of da Vinci procedures in 2025, so international cases still generate less revenue each than domestic ones.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026